CN2885311Y
(zh)
|
2006-01-18 |
2007-04-04 |
郑成福 |
经尿道光动力疗法前列腺治疗仪
|
US10376711B2
(en)
*
|
2003-03-14 |
2019-08-13 |
Light Sciences Oncology Inc. |
Light generating guide wire for intravascular use
|
US20080269846A1
(en)
*
|
2003-03-14 |
2008-10-30 |
Light Sciences Oncology, Inc. |
Device for treatment of blood vessels using light
|
WO2005018556A2
(en)
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo-containing compounds
|
ES2406730T3
(es)
|
2003-08-27 |
2013-06-07 |
3M Innovative Properties Company |
Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
|
AU2004270201A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for CD5+ B cell lymphoma
|
CA2540541C
(en)
|
2003-10-03 |
2012-03-27 |
3M Innovative Properties Company |
Alkoxy substituted imidazoquinolines
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
EP1685129A4
(en)
|
2003-11-14 |
2008-10-22 |
3M Innovative Properties Co |
OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
|
WO2005048945A2
(en)
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Hydroxylamine substituted imidazo ring compounds
|
JP4891088B2
(ja)
|
2003-11-25 |
2012-03-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
置換されたイミダゾ環系および方法
|
JP2007517035A
(ja)
|
2003-12-29 |
2007-06-28 |
スリーエム イノベイティブ プロパティズ カンパニー |
アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
|
CA2551399A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
CA2559863A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US8026366B2
(en)
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006038923A2
(en)
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US7915281B2
(en)
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
AU2005322898B2
(en)
|
2004-12-30 |
2011-11-24 |
3M Innovative Properties Company |
Chiral fused (1,2)imidazo(4,5-c) ring compounds
|
CA2597092A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
EP1869043A2
(en)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
GB0510390D0
(en)
*
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
JP5250967B2
(ja)
*
|
2005-11-30 |
2013-07-31 |
三菱化学株式会社 |
有機化合物、電荷輸送材料、電荷輸送材料用組成物および有機電界発光素子
|
US8022617B2
(en)
|
2005-11-30 |
2011-09-20 |
Mitsubishi Chemical Corporation |
Organic compound, charge-transporting material, composition for charge-transporting material and organic electroluminescent device
|
UA98449C2
(en)
|
2005-12-13 |
2012-05-25 |
Инсайт Корпорейшин |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
WO2007106854A2
(en)
*
|
2006-03-15 |
2007-09-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
|
WO2008008432A2
(en)
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
EA015677B1
(ru)
|
2006-11-20 |
2011-10-31 |
Новартис Аг |
СОЛИ И КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 2-МЕТИЛ-2-[4-(3-МЕТИЛ-2-ОКСО-8-ХИНОЛИН-3-ИЛ-2,3-ДИГИДРОИМИДАЗО[4,5-c]ХИНОЛИН-1-ИЛ)ФЕНИЛ]ПРОПИОНИТРИЛА
|
US9370508B2
(en)
*
|
2007-02-20 |
2016-06-21 |
Novartis Ag |
Imidazoquinolines as dual lipid kinase and mTOR inhibitors
|
US20080234262A1
(en)
*
|
2007-03-21 |
2008-09-25 |
Wyeth |
Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
|
RS53245B2
(sr)
|
2007-06-13 |
2022-10-31 |
Incyte Holdings Corp |
Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
|
EP2170338A2
(en)
*
|
2007-07-06 |
2010-04-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dna-pkcs modulates energy regulation and brain function
|
RU2481838C2
(ru)
*
|
2007-07-24 |
2013-05-20 |
Новартис Аг |
Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
|
US20090082387A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched nvp-bez234
|
CA2708149A1
(en)
*
|
2007-12-13 |
2009-06-18 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
CN101980708B
(zh)
*
|
2008-03-26 |
2013-03-13 |
诺瓦提斯公司 |
作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物
|
MX336723B
(es)
*
|
2008-07-11 |
2016-01-28 |
Novartis Ag |
Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
|
US8791131B2
(en)
|
2008-09-30 |
2014-07-29 |
Pfizer Inc. |
Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
|
RU2519200C2
(ru)
|
2008-10-01 |
2014-06-10 |
Новартис Аг |
Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений
|
TWI378933B
(en)
|
2008-10-14 |
2012-12-11 |
Daiichi Sankyo Co Ltd |
Morpholinopurine derivatives
|
CN102256966B
(zh)
|
2008-10-17 |
2016-02-10 |
白头生物医学研究所 |
可溶性mTOR复合物和其调节剂
|
US9827212B2
(en)
|
2009-03-18 |
2017-11-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating asthma and other lung diseases
|
EP2411387B1
(en)
|
2009-03-27 |
2015-08-19 |
VetDC, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
BRPI1010979A2
(pt)
*
|
2009-05-15 |
2018-03-06 |
Novartis Ag |
"combinação de um inibidor de fosfoinositídeo 3- quinase e de uma composto antidiabético"
|
BRPI1012159B1
(pt)
|
2009-05-22 |
2022-01-25 |
Incyte Holdings Corporation |
Compostos derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d] pirimidinas e pirrol-3-il-pirrolo[2,3-d] pirimidinas como inibidores de janus cinase, composições farmacêuticas compreendendo os referidos compostos e usos dos mesmos
|
LT2432472T
(lt)
|
2009-05-22 |
2020-02-10 |
Incyte Holdings Corporation |
3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- arba heptan-nitrilas, kaip jak inhibitoriai
|
WO2010139747A1
(en)
*
|
2009-06-04 |
2010-12-09 |
Novartis Ag |
1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES
|
MX2011012943A
(es)
|
2009-06-04 |
2012-01-27 |
Novartis Ag |
Derivados de 1h-imidazo-[4,5-c]-quinolinona.
|
CA2766967A1
(en)
*
|
2009-06-30 |
2011-01-06 |
Piramal Life Sciences Limited |
Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
|
EP2451802A1
(en)
|
2009-07-07 |
2012-05-16 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
US20110008372A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Light Sciences Oncology, Inc. |
Enhancement of light activated drug therapy through combination with other therapeutic agents
|
US20120135997A1
(en)
|
2009-07-17 |
2012-05-31 |
Shionogi & Co., Ltd. |
Pharmaceutical composition comprising a lactam or benzenesulfonamide compound
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
GB0919423D0
(en)
*
|
2009-11-05 |
2009-12-23 |
Glaxosmithkline Llc |
Novel compounds
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
AU2011224484A1
(en)
|
2010-03-10 |
2012-09-27 |
Incyte Holdings Corporation |
Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
|
EP2552428A1
(en)
|
2010-03-30 |
2013-02-06 |
Novartis AG |
Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
|
CN103002875B
(zh)
|
2010-05-21 |
2016-05-04 |
因塞特控股公司 |
Jak抑制剂的局部用制剂
|
DE102010025786A1
(de)
*
|
2010-07-01 |
2012-01-05 |
Merck Patent Gmbh |
Pyrazolochinoline
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
AU2011277935B2
(en)
*
|
2010-07-16 |
2015-01-22 |
Piramal Enterprises Limited |
Substituted imidazoquinoline derivatives as kinase inhibitors
|
CN102372712B
(zh)
*
|
2010-08-18 |
2013-10-23 |
山东轩竹医药科技有限公司 |
咪唑并二氮杂萘类PI3K和mTOR双重抑制剂
|
CN102372711B
(zh)
*
|
2010-08-18 |
2014-09-17 |
山东轩竹医药科技有限公司 |
咪唑并喹啉类PI3K和mTOR双重抑制剂
|
BR112013004012B1
(pt)
|
2010-08-20 |
2021-03-23 |
Novartis Ag |
Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
|
CN102382128A
(zh)
*
|
2010-08-27 |
2012-03-21 |
山东轩竹医药科技有限公司 |
三并环的PI3K和mTOR双重抑制剂
|
DE102010035744A1
(de)
*
|
2010-08-28 |
2012-03-01 |
Merck Patent Gmbh |
Imidazolonylchinoline
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
AR083267A1
(es)
*
|
2010-10-04 |
2013-02-13 |
Novartis Ag |
Combinaciones farmaceuticas
|
JP2014503499A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく治療に適した被験体の事前選択
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
ES2536415T3
(es)
|
2010-11-19 |
2015-05-25 |
Incyte Corporation |
Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
|
PE20140146A1
(es)
|
2010-11-19 |
2014-02-06 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
MA34806B1
(fr)
|
2010-12-03 |
2014-01-02 |
Novartis Ag |
Compositions pharmaceutiques
|
AU2011340167A1
(en)
*
|
2010-12-06 |
2013-07-18 |
Piramal Enterprises Limited |
Substituted imidazoquinoline derivatives
|
US20130266590A1
(en)
|
2010-12-13 |
2013-10-10 |
Novartis Ag |
Dimeric iap inhibitors
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
JO3003B1
(ar)
*
|
2011-01-14 |
2016-09-05 |
Lilly Co Eli |
مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
|
JP5957469B2
(ja)
*
|
2011-02-16 |
2016-07-27 |
ノバルティス アーゲー |
神経変性疾患の処置において使用するための治療剤の組み合わせ
|
CN103732226B
(zh)
|
2011-02-18 |
2016-01-06 |
诺瓦提斯药物公司 |
mTOR/JAK抑制剂组合疗法
|
US20120238562A1
(en)
*
|
2011-03-09 |
2012-09-20 |
Cedars-Sinai Medical Center |
Treatment of cancer by targeting molecules that influence mst1/stk4 signaling
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
EP2719697B1
(en)
|
2011-06-04 |
2018-08-01 |
Xuanzhu Pharma Co., Ltd. |
Pyridonaphthyridine pi3k/mtor dual inhibitors and preparation and use thereof
|
AR086983A1
(es)
|
2011-06-20 |
2014-02-05 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
EA030465B1
(ru)
|
2011-07-01 |
2018-08-31 |
Новартис Аг |
Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
|
US9181266B2
(en)
|
2011-07-13 |
2015-11-10 |
Novartis Ag |
2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
|
KR20140051944A
(ko)
|
2011-07-13 |
2014-05-02 |
노파르티스 아게 |
탄키라제 억제제로서 사용하기 위한 4-피페리디닐 화합물
|
CN103814032A
(zh)
|
2011-07-13 |
2014-05-21 |
诺华股份有限公司 |
用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物
|
EP2741747A1
(en)
|
2011-08-10 |
2014-06-18 |
Novartis Pharma AG |
JAK P13K/mTOR COMBINATION THERAPY
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
WO2013066483A1
(en)
|
2011-08-31 |
2013-05-10 |
Novartis Ag |
Synergistic combinations of pi3k- and mek-inhibitors
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
CN103012398B
(zh)
*
|
2011-09-19 |
2015-10-14 |
上海恒瑞医药有限公司 |
咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
|
US20140243396A1
(en)
|
2011-09-30 |
2014-08-28 |
Dana-Farber Cancer Institute, Inc. |
Method of treating mucoepidermoid carcinoma
|
WO2013050921A1
(en)
|
2011-10-03 |
2013-04-11 |
Piramal Enterprises Limited |
Hollow polymer microspheres as three-dimensional cell culture matrix
|
CN103030637A
(zh)
*
|
2011-10-10 |
2013-04-10 |
上海恒瑞医药有限公司 |
咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
|
JP2014530851A
(ja)
|
2011-10-21 |
2014-11-20 |
ノバルティスアーゲー |
Pi3kモジュレータとしてのキナゾリン誘導体
|
AU2012328979B2
(en)
*
|
2011-10-28 |
2016-04-21 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
CA2855619A1
(en)
|
2011-11-15 |
2013-05-23 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2 - signal transducer and activator of transcription 5 pathway
|
JP5820080B2
(ja)
|
2011-11-17 |
2015-11-24 |
山▲東▼▲軒▼竹医▲葯▼科技有限公司 |
三環系PI3K及び/又はmTOR抑制剤
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
CN104105690A
(zh)
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
作为雄激素受体拮抗剂的环状尿素衍生物
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
EP2790705B1
(en)
|
2011-12-15 |
2017-12-06 |
Novartis AG |
Use of inhibitors of the activity or function of pi3k
|
US20150148377A1
(en)
|
2011-12-22 |
2015-05-28 |
Novartis Ag |
Quinoline Derivatives
|
IN2014CN04174A
(es)
|
2011-12-22 |
2015-09-04 |
Novartis Ag |
|
CA2860676A1
(en)
|
2012-01-09 |
2013-07-18 |
Novartis Ag |
Organic compositions to treat beta-catenin-related diseases
|
WO2013154778A1
(en)
|
2012-04-11 |
2013-10-17 |
Dana-Farber Cancer Institute, Inc. |
Host targeted inhibitors of dengue virus and other viruses
|
WO2013173720A1
(en)
|
2012-05-18 |
2013-11-21 |
Incyte Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
RU2014149145A
(ru)
|
2012-05-23 |
2016-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
|
CA2872541A1
(en)
|
2012-06-06 |
2013-12-12 |
Novartis Ag |
Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
|
WO2013192367A1
(en)
|
2012-06-22 |
2013-12-27 |
Novartis Ag |
Neuroendocrine tumor treatment
|
US20150224190A1
(en)
|
2012-07-06 |
2015-08-13 |
Mohamed Bentires-Alj |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction
|
MX369518B
(es)
*
|
2012-08-16 |
2019-11-11 |
Novartis Ag |
Combinacion de inhibidor de p13k e inhibidor de c-met.
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
MY191357A
(en)
|
2012-11-15 |
2022-06-19 |
Incyte Holdings Corp |
Sustained-release dosage forms of ruxolitinib
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
EP2742940B1
(en)
|
2012-12-13 |
2017-07-26 |
IP Gesellschaft für Management mbH |
Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily
|
KR102268357B1
(ko)
|
2013-01-29 |
2021-06-23 |
아벡신 에이에스 |
항염증성 및 항종양성 2-옥소티아졸 및 2-옥소티오펜 화합물
|
EP3360870A1
(en)
|
2013-02-19 |
2018-08-15 |
Novartis AG |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
RU2708032C2
(ru)
|
2013-02-20 |
2019-12-03 |
Новартис Аг |
ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
|
UA120162C2
(uk)
|
2013-03-06 |
2019-10-25 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки при отриманні інгібітора jak
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
WO2014141118A1
(en)
|
2013-03-14 |
2014-09-18 |
Piramal Enterprises Limited |
Imidazo[4,5-c]quinoline derivatives and uses thereof
|
NZ710929A
(en)
|
2013-03-15 |
2018-02-23 |
Novartis Ag |
Antibody drug conjugates
|
MY181085A
(en)
|
2013-03-21 |
2020-12-17 |
Novartis Ag |
Combination therapy
|
WO2014177915A1
(en)
|
2013-05-01 |
2014-11-06 |
Piramal Enterprises Limited |
Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
|
CA2914310A1
(en)
|
2013-06-18 |
2014-12-24 |
Novartis Ag |
Pharmaceutical combinations
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
PT3030227T
(pt)
|
2013-08-07 |
2020-06-25 |
Incyte Corp |
Formas de dosagem de libertação prolongada para um inibidor de jak1
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015041809A2
(en)
|
2013-08-26 |
2015-03-26 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Small molecule cellular reprogramming to generate neuronal cells
|
CN104418858B
(zh)
|
2013-08-30 |
2018-12-11 |
浙江医药股份有限公司新昌制药厂 |
2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
|
US20150140036A1
(en)
|
2013-11-13 |
2015-05-21 |
Novartis Institutes For Biomedical Research, Inc. |
Low, immune enhancing, dose mtor inhibitors and uses thereof
|
WO2015073804A2
(en)
*
|
2013-11-15 |
2015-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of blocking transmission of malarial parasite
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
CN116478927A
(zh)
|
2013-12-19 |
2023-07-25 |
诺华股份有限公司 |
人间皮素嵌合抗原受体及其用途
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
US9815813B2
(en)
|
2014-01-17 |
2017-11-14 |
Novartis Ag |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions therefor for inhibiting the activity of SHP2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
WO2015131080A1
(en)
|
2014-02-28 |
2015-09-03 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
CU24481B1
(es)
|
2014-03-14 |
2020-03-04 |
Immutep Sas |
Moléculas de anticuerpo que se unen a lag-3
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
SG10202109752XA
(en)
|
2014-04-07 |
2021-10-28 |
Novartis Ag |
Treatment of cancer using anti-cd19 chimeric antigen receptor
|
WO2015162584A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Crystalline forms of the sulfate salt of n-[5-(3-imidazol-1-yl-4-methanesulfonyl-phenyl)-4-methyl-thiazol-2-yl]-acetamide
|
NO2714752T3
(es)
|
2014-05-08 |
2018-04-21 |
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
CN105311030B
(zh)
|
2014-06-06 |
2020-03-24 |
正大天晴药业集团股份有限公司 |
用于抗肿瘤的螺取代化合物
|
CN105311029A
(zh)
|
2014-06-06 |
2016-02-10 |
正大天晴药业集团股份有限公司 |
抗肿瘤活性的喹啉衍生物
|
AU2015290007B2
(en)
*
|
2014-07-14 |
2019-11-21 |
Advenchen Pharmaceuticals, Nanjing Ltd. |
Fused quinoline compunds as pi3k, mTor inhibitors
|
EP3169708B1
(en)
|
2014-07-16 |
2019-03-20 |
Dana-Farber Cancer Institute Inc. et Al. |
Her3 inhibition in low-grade serous ovarian cancers
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
WO2016014576A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
GB201413695D0
(en)
|
2014-08-01 |
2014-09-17 |
Avexxin As |
Compound
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
CN117164657A
(zh)
|
2014-08-12 |
2023-12-05 |
莫纳什大学 |
定向淋巴的前药
|
CN106659790A
(zh)
|
2014-08-12 |
2017-05-10 |
诺华股份有限公司 |
抗cdh6抗体药物缀合物
|
CN105330699B
(zh)
*
|
2014-08-13 |
2018-12-04 |
山东汇睿迪生物技术有限公司 |
一种含磷吡啶并[2,3-d]嘧啶-7-酮类化合物或其药学上可接受的盐、药物组合物及其应用
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
GFRα−4キメラ抗原受容体を用いる癌の治療
|
RU2724999C2
(ru)
|
2014-08-19 |
2020-06-29 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
JP6681905B2
(ja)
|
2014-09-13 |
2020-04-15 |
ノバルティス アーゲー |
Alk阻害剤の併用療法
|
WO2016044605A1
(en)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
WO2016057705A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
CR20170143A
(es)
|
2014-10-14 |
2017-06-19 |
Dana Farber Cancer Inst Inc |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
KR20170084202A
(ko)
|
2014-11-14 |
2017-07-19 |
노파르티스 아게 |
항체 약물 접합체
|
EP3221307B1
(en)
|
2014-11-20 |
2019-07-24 |
Council of Scientific & Industrial Research |
Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
|
EP3231797B1
(en)
|
2014-12-09 |
2020-02-26 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Quinoline derivative against non-small cell lung cancer
|
US10689459B2
(en)
|
2014-12-12 |
2020-06-23 |
Novartis Ag |
Treatment of breast cancer brain metastases
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
SI3237418T1
(sl)
|
2014-12-23 |
2019-06-28 |
Novartis Ag |
Spojine triazolopirimidina in njihove uporabe
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
CA2975277A1
(en)
|
2015-03-04 |
2016-09-09 |
Dana-Farber Cancer Institute, Inc. |
Tricyclic kinase inhibitors of melk and methods of use
|
TN2017000375A1
(en)
|
2015-03-10 |
2019-01-16 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
|
FR3033499A1
(fr)
|
2015-03-11 |
2016-09-16 |
Centre Leon-Berard |
Composition pour le traitement des tumeurs neuroendocrines pancreatiques
|
MX2017012295A
(es)
|
2015-03-25 |
2018-01-09 |
Novartis Ag |
Derivados formilados n-heterociclicos como inhibidores de fgfr4.
|
EP3560924B1
(de)
|
2015-04-02 |
2021-03-31 |
Merck Patent GmbH |
Imidazolonylchinoline und deren verwendung als atm-kinase-inhibitoren
|
US20180140602A1
(en)
|
2015-04-07 |
2018-05-24 |
Novartis Ag |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
US20180298068A1
(en)
|
2015-04-23 |
2018-10-18 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
US9751859B2
(en)
|
2015-05-04 |
2017-09-05 |
Advenchen Pharmaceuticals, LLC |
Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine, its crystalline form and its salts
|
CN107847491A
(zh)
|
2015-05-20 |
2018-03-27 |
诺华公司 |
依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
WO2016203405A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
ES2782113T3
(es)
*
|
2015-07-11 |
2020-09-10 |
Advenchen Pharmaceuticals Llc |
Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
|
WO2017019896A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to pd-1
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
PT3317301T
(pt)
|
2015-07-29 |
2021-07-09 |
Novartis Ag |
Terapias de associação compreendendo moléculas de anticorpo contra lag-3
|
CN111821306A
(zh)
|
2015-08-28 |
2020-10-27 |
诺华股份有限公司 |
Mdm2抑制剂和其组合
|
JP6802263B2
(ja)
|
2015-09-02 |
2020-12-16 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
WO2017041139A1
(en)
|
2015-09-08 |
2017-03-16 |
Monash University |
Lymph directing prodrugs
|
WO2017044720A1
(en)
|
2015-09-11 |
2017-03-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
CA3234750A1
(en)
|
2015-10-23 |
2017-04-27 |
Navitor Pharmaceuticals, Inc. |
Modulators of sestrin-gator2 interaction and uses thereof
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
SG11201803520PA
(en)
|
2015-11-03 |
2018-05-30 |
Janssen Biotech Inc |
Antibodies specifically binding pd-1 and their uses
|
EP3383391A1
(en)
|
2015-12-03 |
2018-10-10 |
Novartis AG |
Treatment of cancer with a pi3k inhibitor in a patient preselected for having a pik3ca mutation in the ctdna
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
AU2016369537B2
(en)
|
2015-12-17 |
2024-03-14 |
Novartis Ag |
Antibody molecules to PD-1 and uses thereof
|
ES2965264T3
(es)
|
2016-03-09 |
2024-04-11 |
Raze Therapeutics Inc |
Inhibidores de la 3-fosfoglicerato deshidrogenasa y sus usos
|
EP4234552A3
(en)
|
2016-03-09 |
2023-10-18 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
GB201604316D0
(en)
*
|
2016-03-14 |
2016-04-27 |
Avexxin As |
Combination therapy
|
GB201604318D0
(en)
*
|
2016-03-14 |
2016-04-27 |
Avexxin As |
Combination therapy
|
WO2017177230A1
(en)
|
2016-04-08 |
2017-10-12 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
CN107296811B
(zh)
|
2016-04-15 |
2022-12-30 |
正大天晴药业集团股份有限公司 |
一种用于治疗胃癌的喹啉衍生物
|
DK3452465T3
(da)
|
2016-05-04 |
2021-02-08 |
Genoscience Pharma |
Substituerede 2,4-diaminoquinolinderivater til anvendelse til behandling af proliferative sygdomme
|
RU2744988C2
(ru)
|
2016-06-14 |
2021-03-17 |
Новартис Аг |
Соединения и композиции для подавления активности shp2
|
EP3472161B1
(en)
|
2016-06-20 |
2020-03-25 |
Novartis AG |
Triazolopyridine compounds and uses thereof
|
MX2018016331A
(es)
|
2016-06-20 |
2019-05-20 |
Novartis Ag |
Formas cristalinas de compuesto de triazolopirimidina.
|
CN109790166A
(zh)
|
2016-06-20 |
2019-05-21 |
诺华股份有限公司 |
咪唑并吡啶化合物用于治疗癌症
|
WO2017223229A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
JP6994767B2
(ja)
|
2016-06-21 |
2022-01-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
ES2870920T3
(es)
|
2016-06-21 |
2021-10-28 |
X4 Pharmaceuticals Inc |
Inhibidores de CXCR4 y usos de los mismos
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
EP3481822B1
(en)
|
2016-07-06 |
2022-06-22 |
The Regents of The University of Michigan |
Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
|
CA3031542A1
(en)
|
2016-07-20 |
2018-01-25 |
University Of Utah Research Foundation |
Cd229 car t cells and methods of use thereof
|
CN109789111B
(zh)
|
2016-09-21 |
2021-11-16 |
埃维克辛公司 |
药物组合物
|
JP2019536471A
(ja)
|
2016-09-27 |
2019-12-19 |
セロ・セラピューティクス・インコーポレイテッドCERO Therapeutics, Inc. |
キメラエンガルフメント受容体分子
|
TW202340473A
(zh)
|
2016-10-07 |
2023-10-16 |
瑞士商諾華公司 |
利用嵌合抗原受體之癌症治療
|
US10988472B2
(en)
|
2016-10-13 |
2021-04-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compounds and method for blocking transmission of malarial parasite
|
CN109952303B
(zh)
|
2016-10-14 |
2022-10-21 |
林伯士拉克许米公司 |
Tyk2抑制剂及其用途
|
WO2018075937A1
(en)
|
2016-10-21 |
2018-04-26 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
EP3538091A4
(en)
|
2016-11-08 |
2020-06-10 |
Navitor Pharmaceuticals, Inc. |
PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF
|
WO2018092064A1
(en)
|
2016-11-18 |
2018-05-24 |
Novartis Ag |
Combinations of mdm2 inhibitors and bcl-xl inhibitors
|
TW201825090A
(zh)
|
2016-11-23 |
2018-07-16 |
瑞士商諾華公司 |
增強免疫反應之方法
|
AU2017368050A1
(en)
|
2016-11-29 |
2019-06-20 |
Puretech Lyt, Inc. |
Exosomes for delivery of therapeutic agents
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
AU2017376766A1
(en)
|
2016-12-14 |
2019-06-06 |
Tva (Abc), Llc |
HSP90-targeting conjugates and formulations thereof
|
CN110177791B
(zh)
|
2016-12-20 |
2022-07-12 |
阿斯利康(瑞典)有限公司 |
氨基-三唑并吡啶化合物及其在治疗癌症中的用途
|
HUE056777T2
(hu)
|
2016-12-22 |
2022-03-28 |
Amgen Inc |
Benzizotiazol-, izotiazolo[3,4-b]piridin-, kinazolin-, ftálazin-, pirido[2,3-d]piridazin- és pirido[2,3-d]pirimidin-származékok mint KRAS G12C inhibitorok tüdõ-, hasnyálmirigy- vagy vastagbélrák kezelésére
|
JP2020502238A
(ja)
|
2016-12-23 |
2020-01-23 |
バイスクルアールディー・リミテッド |
新規連結構造を有するペプチド誘導体
|
EP3565638B8
(en)
|
2017-01-06 |
2024-04-10 |
BicycleRD Limited |
Bicycle conjugate for treating cancer
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
TWI783978B
(zh)
|
2017-03-08 |
2022-11-21 |
美商林伯士拉克許米公司 |
Tyk2抑制劑、其用途及生產方法
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
US11339144B2
(en)
|
2017-04-10 |
2022-05-24 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl Rheb inhibitors and uses thereof
|
CN116370448A
(zh)
|
2017-04-26 |
2023-07-04 |
纳维托制药有限公司 |
Sestrin-gator2相互作用的调节剂及其用途
|
US10857196B2
(en)
|
2017-04-27 |
2020-12-08 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
AU2018274216A1
(en)
|
2017-05-24 |
2019-12-12 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
PT3658557T
(pt)
|
2017-07-28 |
2024-09-11 |
Nimbus Lakshmi Inc |
Inibidores de tyk2 e usos dos mesmos
|
JP2020529427A
(ja)
|
2017-08-04 |
2020-10-08 |
バイスクルテクス・リミテッド |
Cd137に対して特異的な二環式ペプチドリガンド
|
AU2018316175B2
(en)
|
2017-08-11 |
2023-02-23 |
The Regents Of The University Of Michigan |
Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
|
US11351176B2
(en)
|
2017-08-14 |
2022-06-07 |
Mei Pharma, Inc. |
Combination therapy
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
EP3668887A1
(en)
|
2017-08-14 |
2020-06-24 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
MA50077A
(fr)
|
2017-09-08 |
2020-07-15 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA50245A
(fr)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals Inc |
Inhibiteurs allostériques octahydrocyclopenta[c]pyrrole de shp2
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
JP7366031B2
(ja)
|
2017-09-22 |
2023-10-20 |
カイメラ セラピューティクス, インコーポレイテッド |
タンパク質分解剤およびそれらの使用
|
AU2018341244A1
(en)
|
2017-09-26 |
2020-03-05 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
EP3727362A4
(en)
|
2017-12-19 |
2021-10-06 |
PureTech LYT, Inc. |
MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
IRAK joints and used in them
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
AU2019212969A1
(en)
|
2018-01-29 |
2020-08-13 |
Merck Patent Gmbh |
GCN2 inhibitors and uses thereof
|
CN111918651B
(zh)
|
2018-01-29 |
2024-01-30 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
KR20200129099A
(ko)
|
2018-01-30 |
2020-11-17 |
인사이트 코포레이션 |
(1-(3-플루오로-2-(트리플루오로메틸)이소니코티닐)피페리딘-4-온)의 제조 방법
|
US10596165B2
(en)
|
2018-02-12 |
2020-03-24 |
resTORbio, Inc. |
Combination therapies
|
AU2019229258B2
(en)
|
2018-02-27 |
2023-09-14 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of TCR-Nck interaction
|
CN115057815A
(zh)
|
2018-03-02 |
2022-09-16 |
正大天晴药业集团股份有限公司 |
作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
|
WO2019180141A1
(en)
|
2018-03-23 |
2019-09-26 |
Bayer Aktiengesellschaft |
Combinations of rogaratinib
|
EP3774906A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
CN112218886A
(zh)
|
2018-03-28 |
2021-01-12 |
森罗治疗公司 |
嵌合吞噬受体的表达载体、基因修饰的宿主细胞及其用途
|
CN112218887A
(zh)
|
2018-03-28 |
2021-01-12 |
森罗治疗公司 |
细胞免疫疗法组合物及其用途
|
CN112423759A
(zh)
|
2018-03-30 |
2021-02-26 |
因赛特公司 |
使用jak抑制剂治疗化脓性汗腺炎
|
CN112218865B
(zh)
|
2018-04-24 |
2024-03-12 |
沃泰克斯药物股份有限公司 |
喋啶酮化合物及其用途
|
CN112236428A
(zh)
|
2018-04-24 |
2021-01-15 |
默克专利股份有限公司 |
抗增殖化合物及其用途
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
CA3098574A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
CN108752336B
(zh)
*
|
2018-05-10 |
2021-06-04 |
常州润诺生物科技有限公司 |
咪唑并喹啉类衍生物及其用途
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
AU2019284472B2
(en)
|
2018-06-11 |
2024-05-30 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
IL279329B1
(en)
|
2018-06-15 |
2024-09-01 |
Navitor Pharm Inc |
Rapamycin analogs and their uses
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
EP3846793B1
(en)
|
2018-09-07 |
2024-01-24 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
EP3853234A1
(en)
|
2018-09-18 |
2021-07-28 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
CN113164776A
(zh)
|
2018-09-25 |
2021-07-23 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
CN113382986A
(zh)
|
2018-09-25 |
2021-09-10 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
KR20210068473A
(ko)
|
2018-09-29 |
2021-06-09 |
노파르티스 아게 |
Shp2 활성 억제용 화합물의 제조 방법
|
EP3866789A4
(en)
|
2018-10-15 |
2022-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
CN112955459A
(zh)
|
2018-10-23 |
2021-06-11 |
拜斯科技术开发有限公司 |
双环肽配体和其用途
|
US11345654B2
(en)
|
2018-10-24 |
2022-05-31 |
Navitor Pharmaceuticals, Inc. |
Polymorphic compounds and uses thereof
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
TWI680973B
(zh)
*
|
2018-11-09 |
2020-01-01 |
長庚學校財團法人長庚科技大學 |
嗜中性白血球發炎抑制劑及其用途
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
MX2021005700A
(es)
|
2018-11-19 |
2021-07-07 |
Amgen Inc |
Inhibidores de kras g12c y metodos de uso de los mismos.
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MX2021006154A
(es)
|
2018-11-30 |
2021-08-24 |
Kymera Therapeutics Inc |
Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
|
US11053241B2
(en)
|
2018-11-30 |
2021-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
CA3123227A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
MX2021007156A
(es)
|
2018-12-20 |
2021-08-16 |
Amgen Inc |
Inhibidores de kif18a.
|
CN113195541B
(zh)
|
2018-12-21 |
2024-08-30 |
诺华股份有限公司 |
针对pmel17的抗体及其缀合物
|
JP2022518505A
(ja)
|
2019-01-23 |
2022-03-15 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
US20230148450A9
(en)
|
2019-03-01 |
2023-05-11 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
US11485750B1
(en)
|
2019-04-05 |
2022-11-01 |
Kymera Therapeutics, Inc. |
STAT degraders and uses thereof
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
GB201906864D0
(en)
|
2019-05-15 |
2019-06-26 |
Avexxin As |
Combination therapy
|
GB201906867D0
(en)
|
2019-05-15 |
2019-06-26 |
Avexxin As |
Combination therapy
|
US11236091B2
(en)
|
2019-05-21 |
2022-02-01 |
Amgen Inc. |
Solid state forms
|
JP2022534425A
(ja)
|
2019-05-31 |
2022-07-29 |
イケナ オンコロジー, インコーポレイテッド |
Tead阻害剤およびその使用
|
WO2021001743A1
(en)
|
2019-07-02 |
2021-01-07 |
Effector Therapeutics, Inc. |
Translation inhibitors and uses thereof
|
GB201910644D0
(en)
|
2019-07-25 |
2019-09-11 |
Coegin Pharma As |
Cancer Treatment
|
TW202110485A
(zh)
|
2019-07-30 |
2021-03-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
JP2022542319A
(ja)
|
2019-08-02 |
2022-09-30 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤
|
CN114269731A
(zh)
|
2019-08-02 |
2022-04-01 |
美国安进公司 |
Kif18a抑制剂
|
MX2022001952A
(es)
|
2019-08-15 |
2022-06-02 |
Black Diamond Therapeutics Inc |
Compuestos de alquinil quinazolina.
|
AU2020345962A1
(en)
|
2019-09-11 |
2022-03-31 |
Vincere Biosciences, Inc. |
USP30 inhibitors and uses thereof
|
BR112022004451A2
(pt)
|
2019-09-13 |
2022-06-21 |
Nimbus Saturn Inc |
Antagonistas de hpk1 e usos dos mesmos
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
US20230014730A1
(en)
|
2019-09-23 |
2023-01-19 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphodiesterase inhibitors and use
|
AU2020353005A1
(en)
*
|
2019-09-23 |
2022-04-14 |
Nanjing Zhengxiang Pharmaceuticals Co., Ltd. |
Phosphodiesterase inhibitors and use
|
JP2022550353A
(ja)
|
2019-09-26 |
2022-12-01 |
ノバルティス アーゲー |
アザキノリン化合物およびその使用
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
EP4045047A1
(en)
|
2019-10-15 |
2022-08-24 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
CN114867726B
(zh)
|
2019-10-28 |
2023-11-28 |
默沙东有限责任公司 |
Kras g12c突变体的小分子抑制剂
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
WO2021087432A1
(en)
|
2019-11-01 |
2021-05-06 |
Navitor Pharmaceuticals, Inc. |
Methods of treatment using an mtorc1 modulator
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
JP2022553859A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
CA3159561A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
US20210139517A1
(en)
|
2019-11-08 |
2021-05-13 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
CN111187181B
(zh)
*
|
2019-11-22 |
2023-05-05 |
吉林大学 |
一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
US11819476B2
(en)
|
2019-12-05 |
2023-11-21 |
Janssen Pharmaceutica Nv |
Rapamycin analogs and uses thereof
|
WO2021126816A1
(en)
|
2019-12-16 |
2021-06-24 |
Amgen Inc. |
Dosing regimen of a kras g12c inhibitor
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
CN115297931A
(zh)
|
2019-12-23 |
2022-11-04 |
凯麦拉医疗公司 |
Smarca降解剂和其用途
|
AU2021206217A1
(en)
|
2020-01-07 |
2022-09-01 |
Revolution Medicines, Inc. |
SHP2 inhibitor dosing and methods of treating cancer
|
KR20220149534A
(ko)
|
2020-02-05 |
2022-11-08 |
퓨어테크 엘와이티, 아이엔씨. |
신경스테로이드의 지질 전구약물
|
WO2021178488A1
(en)
|
2020-03-03 |
2021-09-10 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス, インコーポレイテッド |
Mdm2分解剤およびそれらの使用
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
US20230181536A1
(en)
|
2020-04-24 |
2023-06-15 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
BR112022025550A2
(pt)
|
2020-06-18 |
2023-03-07 |
Revolution Medicines Inc |
Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
|
JP2023539715A
(ja)
|
2020-06-24 |
2023-09-19 |
アストラゼネカ ユーケー リミテッド |
抗体-薬物コンジュゲートとatm阻害剤との組合わせ
|
EP4183395A4
(en)
|
2020-07-15 |
2024-07-24 |
Taiho Pharmaceutical Co Ltd |
PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
|
AR123185A1
(es)
|
2020-08-10 |
2022-11-09 |
Novartis Ag |
Compuestos y composiciones para inhibir ezh2
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
WO2022038158A1
(en)
|
2020-08-17 |
2022-02-24 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
WO2022043558A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
WO2022043556A1
(en)
|
2020-08-31 |
2022-03-03 |
Novartis Ag |
Stable radiopharmaceutical composition
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
CA3194067A1
(en)
|
2020-09-15 |
2022-03-24 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4142710B1
(en)
|
2020-09-21 |
2024-01-31 |
Wei Zhong |
Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
CA3200814A1
(en)
|
2020-12-02 |
2022-06-09 |
Alfredo C. Castro |
Tead inhibitors and uses thereof
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
WO2022140472A1
(en)
|
2020-12-22 |
2022-06-30 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
EP4288427A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
US20230091528A1
(en)
|
2021-02-02 |
2023-03-23 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
US20240139183A1
(en)
|
2021-02-16 |
2024-05-02 |
Ribotech Co., Ltd. |
Compound for suppressing nonsense-mediated mrna decay
|
CN117203223A
(zh)
|
2021-02-26 |
2023-12-08 |
凯洛尼亚疗法有限公司 |
淋巴细胞靶向慢病毒载体
|
WO2022187856A1
(en)
|
2021-03-05 |
2022-09-09 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
WO2022221720A1
(en)
|
2021-04-16 |
2022-10-20 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
AU2022258968A1
(en)
|
2021-04-16 |
2023-10-19 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
CN115232122B
(zh)
*
|
2021-04-23 |
2024-05-31 |
石药集团中奇制药技术(石家庄)有限公司 |
炔类化合物及其制备和应用
|
AR125787A1
(es)
|
2021-05-05 |
2023-08-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
PE20240088A1
(es)
|
2021-05-05 |
2024-01-16 |
Revolution Medicines Inc |
Inhibidores de ras
|
TW202309030A
(zh)
|
2021-05-07 |
2023-03-01 |
美商凱麥拉醫療公司 |
Cdk2降解劑及其用途
|
WO2022250170A1
(en)
|
2021-05-28 |
2022-12-01 |
Taiho Pharmaceutical Co., Ltd. |
Small molecule inhibitors of kras mutated proteins
|
EP4370522A1
(en)
|
2021-07-14 |
2024-05-22 |
Nikang Therapeutics, Inc. |
Alkylidene derivatives as kras inhibitors
|
EP4376874A1
(en)
|
2021-07-28 |
2024-06-05 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
TW202315621A
(zh)
|
2021-08-25 |
2023-04-16 |
美商皮克醫療公司 |
Eif4e抑制劑及其用途
|
JP2024532276A
(ja)
|
2021-08-25 |
2024-09-05 |
ピク セラピューティクス, インコーポレイテッド |
eIF4E阻害剤及びその使用
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
AU2022425324A1
(en)
|
2021-12-30 |
2024-05-30 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Tricyclic derivative inhibitor, preparation method therefor, and application thereof
|
AU2023214044A1
(en)
|
2022-01-31 |
2024-08-08 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023192801A1
(en)
|
2022-03-28 |
2023-10-05 |
Nikang Therapeutics, Inc. |
Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
TW202416950A
(zh)
|
2022-08-02 |
2024-05-01 |
英商利米那生物科技有限公司 |
雜芳基甲醯胺及相關gpr84拮抗劑及其用途
|
TW202415650A
(zh)
|
2022-08-02 |
2024-04-16 |
英商利米那生物科技有限公司 |
芳基-三唑基及相關gpr84拮抗劑及其用途
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024102849A1
(en)
|
2022-11-11 |
2024-05-16 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
US20240208961A1
(en)
|
2022-11-22 |
2024-06-27 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2024206858A1
(en)
|
2023-03-30 |
2024-10-03 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
WO2024211663A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|